BioNTech Prepares for First US Cancer Drug Submission Amidst Widest Clinical Pipeline Yet
Veröffentlicht: 12.06.2026 um 04:53 Uhr, Redaktion boerse-global.de
BioNTech is gearing up for the most consequential regulatory filing in its corporate history. The Mainz-based biotech plans to submit Trastuzumab Pamirtecan to the US Food and Drug Administration in 2026, targeting an initial approval in uterine cancer. Phase 2 data showed a response rate of nearly 48% in heavily pretreated patients, with median progression-free survival clocking in at 8.1 months. Among the high-risk subgroup, tumors shrank in over 70% of those treated. The FDA has already granted breakthrough therapy designation, and a parallel approval process is underway in China since April.
That submission is just one piece of a far broader oncology push. BioNTech now expects to have 15 pivotal studies either running or planned by year-end, with seven late-stage data packages slated for release in 2026 alone. The company is running more than 25 Phase 2 and Phase 3 oncology trials concurrently — more than double the count two years ago. Five additional pivotal studies for the bispecific antibody Pumitamig, developed jointly with Bristol Myers Squibb, were launched this year. The candidate targets both PD-L1 and VEGF-A, and the third global dataset from the ongoing ROSETTA Lung-02 trial in first-line non-small cell lung cancer showed consistent anti-tumor activity across independent cohorts. On a separate front, Gotistobart delivered durable responses and clinically meaningful overall survival data in platinum-resistant ovarian cancer patients from the PRESERVE-004 Phase 2 study, with a manageable safety profile that could support a chemotherapy-free option.
The pipeline’s breadth now extends beyond lung and gynecologic cancers to include breast, gastrointestinal, and urogenital tumors via immunomodulators, antibody-drug conjugates, and mRNA-based cancer immunotherapies. That expansion speed is unusual even for larger biotech peers. Yet the stock trades as if little of this progress has registered. BioNTech shares closed at 77.60 euros, roughly 27% below the 52-week high of 105.80 euros and nearly 10% under the 200-day moving average. The relative strength index sits at 47.2, indicating neither oversold nor overbought conditions, while the stock is 4.3% below its 50-day average.
Should investors sell immediately? Or is it worth buying BioNTech?
The financial transition is raw. First-quarter revenue came in at 118.1 million euros — down 35% year over year — against a net loss of 531.9 million euros. Management maintained its full-year revenue guidance of 2.0 to 2.3 billion euros, but acknowledged that legacy COVID-vaccine sales will keep declining and that no oncology product revenue is expected in 2026. The bull case rests on the idea that the oncology investment will eventually more than compensate for that erosion, but Phase 2 data, however promising, does not guarantee Phase 3 success.
Wall Street’s sell-side is nevertheless leaning bullish. The consensus price target stands at 106.70 euros, implying upside of nearly 38% from current levels. UBS upgraded the stock to Buy on May 26 with a 135-dollar target following the ASCO data cycle. Canaccord Genuity sees fair value at 158 dollars, while Bernstein Research strikes a more cautious note, rating the stock Market Perform with a 96-dollar target. No analyst currently recommends selling.
The bear case is not trivial: shrinking legacy revenue, no near-term oncology sales, mounting losses, and the ever-present risk of clinical or regulatory setbacks. But the gap between clinical momentum and market valuation is widening. At 77.60 euros, investors are being offered a discount that reflects legitimate Phase 3 execution risk — not a value trap. With six more pivotal data readouts expected by the end of the year, each one represents a chance to close that gap. The FDA submission for Trastuzumab Pamirtegan will be the clearest signal yet that BioNTech’s pivot from vaccine maker to oncology powerhouse is no longer a promise — it’s a countdown.
Ad
BioNTech Stock: New Analysis - 12 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
